Filing Flows › 8-K events › BRC Group Holdings
BRC Group Holdings: completion of an acquisition or disposition of assets
Form 8-K filed Nov 5, 2026 · items 1.01, 2.01, 2.03
What the filing says
The GA Transaction constituted a significant disposition for purposes of Item 2.01 of Form 8-K. Accordingly, the pro forma information required by Item 9.01 of Form 8-K will be filed as an amendment to this Form 8-K no later than November 9, 2026.
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.01: +0.1% next session across 2,671. Item 2.03: 0.0% next session across 13,268. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.
Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.
BRC Group Holdings at a glance
BRC Group Holdings, Q3 2026: revenue $33.0M (-88% year over year), operating margin -423.0%. The chart follows the revenue to costs, profit and cash.
BRC Group Holdings: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent debt and financing
- Airsculpt Technologies Nov 6, 2026
- Starry Sea Acquisition Nov 6, 2026
- Repligen Nov 6, 2026
- Evertec Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Reed's Nov 6, 2026
- Protagenic Therapeutics, Inc.\new Nov 6, 2026
- CNL Strategic Residential Credit Nov 6, 2026
- Health In Tech Nov 6, 2026
- Profusa Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.